Bevicra 400 mg Injection
  1. Home
  2. Pharma Products
  3. Glenmark Pharmaceuticals Ltd
  4. Bevicra 400 mg Injection

Bevicra 400 mg Injection

Bevicra 400 mg Injection contains bevacizumab 400 mg and is an anticancer medicine used in the treatment of several types of cancer. It is administered by intravenous infusion under the supervision of a qualified healthcare professional. Bevacizumab works by blocking VEGF, a protein that supports the formation of new blood vessels needed for tumor growth.

BUY NOW

Category

Bevicra is a monoclonal antibody that targets vascular endothelial growth factor and helps inhibit tumor angiogenesis. It may be used with other anticancer medicines in appropriate treatment regimens for colorectal, lung, kidney, ovarian, cervical, and other cancers. The dose and infusion schedule depend on the cancer type, treatment regimen, and individual patient factors. Medical monitoring is important because bevacizumab may cause hypertension, bleeding, proteinuria, impaired wound healing, and infusion-related reactions.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 400 mg
Presentation 400 mg/16 mL
Concentration 25 mg/mL
Dosage Form Solution for Infusion
Route of Administration Intravenous Infusion

Product Also Known As

Bevicra 400mg Injection, Bevicra 400mg/16ml Injection, Bevacizumab 400mg Injection, Bevacizumab 400mg/16ml Infusion, Bevacizumab Injection 400mg, Bevacizumab 25mg/ml Infusion